Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life.
Chronic prurigo
Dupilumab
Quality of life
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
09
2022
accepted:
28
05
2023
medline:
1
11
2023
pubmed:
28
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Chronic prurigo (CPG) is a pruritic skin disease, characterized by an itch-scratch cycle and scarring. It reduces patients' quality of life (QoL). Dupilumab is a monoclonal human IgG antibody that inhibits signaling of the interleukin 4 (IL-4) and interleukin 13 (IL-13) pathways through blockade of the IL-4 receptor. Patients with CPG who receive dupilumab often report great improvement in itch and overall QoL. We therefore reviewed our experience in order to follow up on QoL, safety, and treatment response in patients with CPG who received dupilumab. We conducted a real-world retrospective single-center case series. Outcomes were assessed by phone interviews and photographs using validated questionnaires and scores. Demographic data were obtained from the hospital files. Follow-up was up to 2 years. We assessed QoL with the Dermatology Life Quality Index (DLQI) and the Itchy quality of life questionnaire (ItchyQoL). Numerical Rating Scale (NRS) was used to assess itch. Prurigo lesions were documented with the Prurigo activity and severity score (PAS). Ten patients were included in this study. Results were reported up to 2 years after treatment with dupilumab. The response variables for DLQI, ItchyQoL, NRS, and PAS analyses showed a statistically significant decrease over time (DLQI: p ≤ 0.0001 [-0.84; -1.27], ItchyQoL: p ≤ 0.0001 [-9.89; -18.69], NRS maximum and average: p ≤ 0.0001 [-0.52; -0.86] and p ≤ 0.0001 [-0.55; -0.94], and PAS number of lesions: p = 0.0005 [-1.70; -5.28]). The percent decrease after 1 year of treatment (this estimate is based on model estimates) ranges from -42% to -82%. Four (40%) patients reported mild side effects. No serious side effects were reported. Dupilumab treatment of CGP for up to 2 years is associated with improved QoL and less itching.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic prurigo (CPG) is a pruritic skin disease, characterized by an itch-scratch cycle and scarring. It reduces patients' quality of life (QoL). Dupilumab is a monoclonal human IgG antibody that inhibits signaling of the interleukin 4 (IL-4) and interleukin 13 (IL-13) pathways through blockade of the IL-4 receptor. Patients with CPG who receive dupilumab often report great improvement in itch and overall QoL. We therefore reviewed our experience in order to follow up on QoL, safety, and treatment response in patients with CPG who received dupilumab.
METHODS
METHODS
We conducted a real-world retrospective single-center case series. Outcomes were assessed by phone interviews and photographs using validated questionnaires and scores. Demographic data were obtained from the hospital files. Follow-up was up to 2 years. We assessed QoL with the Dermatology Life Quality Index (DLQI) and the Itchy quality of life questionnaire (ItchyQoL). Numerical Rating Scale (NRS) was used to assess itch. Prurigo lesions were documented with the Prurigo activity and severity score (PAS).
RESULTS
RESULTS
Ten patients were included in this study. Results were reported up to 2 years after treatment with dupilumab. The response variables for DLQI, ItchyQoL, NRS, and PAS analyses showed a statistically significant decrease over time (DLQI: p ≤ 0.0001 [-0.84; -1.27], ItchyQoL: p ≤ 0.0001 [-9.89; -18.69], NRS maximum and average: p ≤ 0.0001 [-0.52; -0.86] and p ≤ 0.0001 [-0.55; -0.94], and PAS number of lesions: p = 0.0005 [-1.70; -5.28]). The percent decrease after 1 year of treatment (this estimate is based on model estimates) ranges from -42% to -82%. Four (40%) patients reported mild side effects. No serious side effects were reported.
CONCLUSION
CONCLUSIONS
Dupilumab treatment of CGP for up to 2 years is associated with improved QoL and less itching.
Identifiants
pubmed: 37369187
pii: 000531708
doi: 10.1159/000531708
pmc: PMC10614240
doi:
Substances chimiques
dupilumab
420K487FSG
Antibodies, Monoclonal
0
Interleukin-13
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
811-817Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Skin Therapy Lett. 2021 May;26(3):5-8
pubmed: 34077168
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):958-964
pubmed: 33332697
Dermatol Ther. 2020 Mar;33(2):e13222
pubmed: 31917498
J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):162-163
pubmed: 32573461
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1059-1065
pubmed: 28857299
Acta Derm Venereol. 2019 Sep 1;99(10):905-906
pubmed: 31233177
J Eur Acad Dermatol Venereol. 2013 May;27(5):550-7
pubmed: 22364653
Cell. 2017 Sep 21;171(1):217-228.e13
pubmed: 28890086
Br J Dermatol. 2017 May;176(5):1170-1178
pubmed: 28032340
Medicines (Basel). 2019 Jun 29;6(3):
pubmed: 31261951
J Dermatol. 2021 May;48(5):638-644
pubmed: 33742710
J Am Acad Dermatol. 2020 Jul;83(1):39-45
pubmed: 32229281
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):391-397
pubmed: 30193410
Dermatitis. 2020 Jan/Feb;31(1):81-84
pubmed: 31517666
J Allergy Clin Immunol. 2018 Nov;142(5):1375-1390
pubmed: 30409247
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):e285-e287
pubmed: 33232536
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e74-e76
pubmed: 31529718
J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1754-1760
pubmed: 29729201
Clin Exp Allergy. 2020 Jan;50(1):5-14
pubmed: 31505066
J Dermatolog Treat. 2022 May;33(3):1547-1553
pubmed: 33200955
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Am J Clin Dermatol. 2020 Aug;21(4):567-577
pubmed: 32557382
Dermatol Clin. 2018 Jul;36(3):189-197
pubmed: 29929592
Expert Opin Biol Ther. 2022 Jan;22(1):47-58
pubmed: 34289753
J Dtsch Dermatol Ges. 2011 Jan;9(1):12-20
pubmed: 21054785
J Eur Acad Dermatol Venereol. 2022 Apr;36(4):573-581
pubmed: 34908192
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1541-1551
pubmed: 35569006
Acta Derm Venereol. 2018 Feb 7;98(2):173-179
pubmed: 29135018
Acta Derm Venereol. 2021 Feb 17;101(2):adv00403
pubmed: 33320272